Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis (CP3)

Overview

About this study

The purpose of this study is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Willing and able to provide informed consent
  2. Male or female aged 40-75
  3. Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis

Exclusion Criteria:

  1. Currently taking a prescription lipid lowering medication
  2. Pregnant or planning pregnancy in the next 6 months
  3. Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/30/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Stella Chen

Open for enrollment

Contact information:

Samantha Devlin

(480) 301-6479

Cosby.Samantha@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597060

Mayo Clinic Footer